Fierce Pharma April 26, 2024
Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out of prominent industry lobbying group the Biotechnology Innovation Organization (BIO).
As the Japanese pharma wraps up its fiscal year, the company opted not to renew its membership after a “routine review of our trade association participation,” a spokesperson said in an emailed statement.
“We believe it will allow us to further refine the focus of our resources and continue to play an active role in advancing innovation and advocating for policies that put patients first while improving the global health care ecosystem,” the Takeda representative added.
Takeda is the fourth company to leave BIO since December. The latest exit follows...
Today's Sponsors
Today's Sponsor